A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)

NCT07058012 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

79

Enrollment

NETWORK

Sponsor class

Conditions

Colo-rectal Cancer

Interventions

DRUG: Cemiplimab
DRUG: cemiplimab plus fianlimab
DRUG: cemiplimab + REGN7075
OTHER: ctDNA testing

Sponsor

NSABP Foundation Inc

Collaborators

[object Object]